| Aug 14 |
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update
|
| Aug 13 |
Outlook Therapeutics Q3 2024 Earnings Preview
|
| Aug 12 |
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
|
| Aug 9 |
Why Is Caligan Partners Bullish on Outlook Therapeutics Inc (OTLK) Right Now?
|
| Aug 7 |
Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast
|
| Jul 30 |
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
|
| Jul 8 |
Outlook Therapeutics announces UK marketing authorization of its wet AMD treatment
|
| Jul 8 |
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
|
| Jun 25 |
3 Undervalued Gems Set to Soar 1,000% by 2026
|
| Jun 19 |
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private equity firms own 31%
|
